AiCuris
The Anti-Infectives Powerhouse
AiCuris GmbH & Co. KG, Friedrich-Ebert-Str. 475, 42117 Wuppertal- Germany
T: +49 (0)202 317 63 - 0, E-mail: info@aicuris.com, Web: www.aicuris.com

Company Profile

AiCuris (from Anti-Infective Cures) was founded in March 2006 as a spin-off of the anti-infectives Unit of Bayer Health Care. Since then, AiCuris has become a highly focused pharmaceutical company in drug discovery, research, and development of novel antiviral and antibacterial agents for the treatment of severe and life-threatening infectious diseases. AiCuris’ Head Office and R&D facilities are located at the Life Science Park in Wuppertal, Germany, where the company occupies 3,000 square meters of purpose built biology and pharmacokinetics facilities for the discovery and development of novel anti-infective agents.

Team

AiCuris is led by an experienced management team and supported financially by the founders and previous owners of Hexal. At the company’s heart is a team of scientists with broad international experience in drug discovery and development, knowledge gained at both large and small pharmaceutical companies. The team has core expertise in pharmacology, bacteriology, virology, pharmacokinetics, medicinal chemistry and clinical development.

Mission & Pipeline

AiCuris is committed to anti-infective drug discovery and specially determined to develop life-saving options for severe Gram-positive and Gram-negative infections to ensure effective antibiotics for the future. The company’s highly innovative antibacterial pipeline comprises several discovery programs as well as one late stage preclinical candidate (AIC499) targeting multi-drug resistant pathogens. The projects are mainly derived from novel compound classes with new modes of action against diverse bacterial targets and without cross-resistance to any marketed antibiotics. AiCuris’ strong antibacterial and antiviral portfolio and current development status is depicted in the below pipeline.

Hospital antibiotics

According to the U.S. Center for Disease Control and Prevention (CDC), of all of the bacterial resistance problems, Gram-negative pathogens are particularly worrisome. This is due to the constantly increasing development of resistance against almost all available and marketed antibiotic classes. In fact, Gram-negative bacteria are considered to be amongst the most serious threats to public health and society, with healthcare-associated infections representing the biggest challenge worldwide. Most common Gram-negative pathogens responsible for such threats include Enterobacteria, P. aeruginosa and Acinetobacter.

AIC499- a novel β-lactam

AIC499 is an innovative β-lactam antibiotic which addresses the urgent unmet medical need arising from hospital-acquired infections with Gram-negative bacteria. In combination with a beta-lactamase inhibitor (BLI), AIC499 shows very potent and targeted antibacterial activity against Gram-negative pathogens including multi-drug resistant strains of P. aeruginosa and Acinetobacter. Due to its unique profile and extensive coverage, AIC499 has the potential to become the best treatment option for present and future resistant Gram-negative infections. The clinical Phase I trials – planned for 2015 - and the clinical Phase 2 trials will be conducted within the IMI funded Consortium “COMBACTE-MAGNET”.

Summary

With a broad portfolio of anti-infective drugs in specialized indications with profound medical need, AiCuris is aimed squarely at one of the largest pharmaceutical markets with strong growth potential, particularly in emerging countries.

AiCuris has proven its ability to develop its portfolio rapidly and effectively and is actively pursuing the discovery of novel therapies in the area of infectious diseases. The company has developed a broad and innovative pipeline of novel anti-infectives and employs a team of internationally recognized scientists and drug developers.

With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.